已收盤 09-03 16:00:00 美东时间
0.000
0.00%
Gainers Pelthos Therapeutics (AMEX:PTHS) stock increased by 25.9% to $28.27 du...
09-04 01:06
AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User EcosystemBrittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointed Chief Executive
09-03 21:10
AlphaTON Capital has announced plans to acquire approximately $100 million worth of TON tokens to establish a digital asset treasury and integrate with Telegram's billion-user ecosystem. The company, formerly Portage Biotech Inc. (Nasdaq: PRTG), will trade under the new ticker symbol "ATON" starting September 4, 2025. Brittany Kaiser, a prominent figure in digital assets and data protection, has been appointed as CEO and board member. The strateg...
09-03 16:37
Shares of Worthington Steel, Inc. (NYSE:WS) rose sharply in today's pre-market ...
06-26 17:12
Portage Biotech Inc ( ($PRTG) ) has shared an update. On June 24, 2025, Portage...
06-25 19:49
Portage Biotech (NASDAQ:PRTG) received formal notice from Nasdaq that the company has evidenced compliance with all applicable requirements for continued listing. The company had previously received...
06-25 19:38
Portage Biotech Inc. announced that it has met all applicable requirements for continued listing on The Nasdaq Capital Market. The company, a clinical-stage immuno-oncology firm developing novel biologics to enhance the immune system's ability to fight cancer, received formal notice from Nasdaq on June 24, 2025. Portage Biotech aims to transform cancer treatment through its innovative pipeline. The company also noted that forward-looking statemen...
06-25 11:00
Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,165,501 shares of Compedica with a value of $4.29 per share, in a transaction valued at
06-09 18:04
Portage Biotech and Compedica Holdings have entered a Subscription Agreement, with Portage issuing 625,000 shares worth $8 each for 1.165 million Compedica shares valued at $4.29 each, totaling $5 million. Compedica now owns 27.4% of Portage's shares. The partnership aims to support the development and commercialization of Compedica's OptiPulse medical device for treating diabetic foot ulcers, a market valued over $4 billion in the U.S. Compedica...
06-09 10:00
Portage Biotech stock jumped after new PORT-7 data showed enhanced immune response and plans advanced for combined A2A and A2B receptor blockade.
04-28 22:37